SELECTIVE ACTIVATION OF ANTIFUNGAL PRODRUGS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$299,488.00
Award Year:
2002
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI050258-01A1
Award Id:
60512
Agency Tracking Number:
AI050258
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
HAWAII BIOTECH, INC., 99-193 AIEA HEIGHTS DR, STE 236, AIEA, HI, 96701
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SEAN OMALLEY
(808) 486-5333
STAFF@HIBIOTECH.COM
Business Contact:
DAVID WATUMULL
(808) 486-5333
STAFF@HIBIOTECH.COM
Research Institution:
n/a
Abstract
DESCRIPTION (Provided by applicant): The proposed research will investigate the feasibility of utilizing inherent properties of the infection site as a means to activate antifungal prodrugs selectively. Prodrug derivatives of an antifungal agent will be prepared and tested for their susceptibility to activation by conditions present at infection sites of C. albicans. Test compounds will be analyzed both in vitro and in vivo to determine their selectivity for the fungal infection. Promising leads will be those compounds which are both easily activated by these conditions and are resistant to activation in the normal mammalian physiological environment. Phase II will optimize the prodrug design based on our lead candidates and take this second generation design into preclinical testing.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government